SI-BONE, Inc.
NASDAQ:SIBNMedical - Devices
+$0.53 today
- Market cap
- $1.06B
- Beta
- 0.70
- P/E (TTM)
- -41.4
- EPS (TTM)
- -$0.38
Volume 1.12M
Average 0.68M
SIBN EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
SI-BONE, Inc.NASDAQ: SIBN
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$2.13M, compared with -$4.6M a year earlier. Trailing-twelve-month EBITDA was -$5.99M.
Context
- EBITDA amounted to 5.4% of revenue in FY2025, down 8.4 pp from a year earlier.
- EBITDA grew in size in 0 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 6 analysts of -$5.75M (+47.3%) for the fiscal year ending Dec 2026, a slowdown from the +52.8% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$2.13M-179.8% QoQ
- Last fiscal yearDec 2025
- -$10.91M+52.8% YoY
- LTMMar 2026
- -$5.99M+68.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +53.8% | -1.2% | -55.1 pp |
| 1 year | +52.8% | +47.3% | -5.5 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (10.91M) USD
- Year-over-year change
- +52.8%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (10.91M) | +52.8% |
| FY2024 | 2024-12-31 | (23.09M) | +33.0% |
| FY2023 | 2023-12-31 | (34.45M) | +37.4% |
| FY2022 | 2022-12-31 | (54.99M) | -7.9% |
| FY2021 | 2021-12-31 | (50.97M) | — |
EBITDA vs competitors
How SIBN compares with its peers on the latest reported figures
- SIBN's LTM Mar 2026 EBITDA of -$5.99M is the lowest of the 6 companies compared; the peer median is $945.76M.
- Its year-over-year change of +68.1% is the 2nd highest of 6, against a peer median of +40.7%.
- EBITDA amounts to 2.9% of revenue for SIBN, versus a peer median of 21.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $6.69B | +40.7% | +16.3% | 25.9% | |
| FY2025 | $1.34B | +0.1% | +5.1% | 21.7% | |
| LTM Jun 2026 | $945.76M | +52.8% | +42.8% | 30.1% | |
| LTM Mar 2026 | $169.63M | -31.6% | +170.6% | 12.4% | |
| LTM Mar 2026 | -$1.36M | +97.4% | — | 0.2% | |
| LTM Mar 2026 | -$5.99M | +68.1% | — | 2.9% | |
| Peer median (excluding SIBN) | $945.76M | +40.7% | +29.5% | 21.7% | |
Competitors are the stored peer set for SIBN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 90.15M | 106.41M | 138.89M | 167.18M | 200.93M |
| Cost of Revenue | 10.43M | 15.71M | 29.47M | 35.06M | 41.05M |
| Gross Profit | 79.72M | 90.7M | 109.42M | 132.12M | 159.88M |
| Gross Margin | 88.4% | 85.2% | 78.8% | 79.0% | 79.6% |
| Research & Development | 12.44M | 13.63M | 15.03M | 16.56M | 17.45M |
| Selling, General & Admin | 118.95M | 136.69M | 141.32M | 150.81M | 164.76M |
| Operating Expenses | 131.39M | 150.31M | 156.35M | 167.37M | 182.21M |
| Depreciation & Amortization | 2.09M | 3.45M | 5.43M | 4.38M | 2.72M |
| EBITDA | (50.97M) | (54.99M) | (34.45M) | (23.09M) | (10.91M) |
| EBITDA Margin | -56.5% | -51.7% | -24.8% | -13.8% | -5.4% |
| Operating Income | (51.67M) | (59.61M) | (46.93M) | (35.25M) | (22.33M) |
| Operating Margin | -57.3% | -56.0% | -33.8% | -21.1% | -11.1% |
| Interest Income | 186K | 1.3M | 6.92M | 7.85M | 6.07M |
| Interest Expense | 5.37M | 2.82M | 3.46M | 3.44M | 5.28M |
| Other Income / Expenses | (4.9M) | (1.65M) | 3.6M | 4.34M | 3.42M |
| Income Before Tax | (56.57M) | (61.26M) | (43.34M) | (30.91M) | (18.91M) |
| Pre-Tax Margin | -62.8% | -57.6% | -31.2% | -18.5% | -9.4% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (56.57M) | (61.26M) | (43.34M) | (30.91M) | (18.91M) |
| Net Margin | -62.8% | -57.6% | -31.2% | -18.5% | -9.4% |
| EPS (Basic) | (1.71) | (1.79) | (1.13) | (0.75) | (0.44) |
| EPS (Diluted) | (1.71) | (1.79) | (1.13) | (0.75) | (0.44) |
| Weighted Avg Shares | 33.15M | 34.2M | 38.43M | 41.47M | 43.51M |
| Weighted Avg Shares (Diluted) | 33.15M | 34.2M | 38.43M | 41.47M | 43.51M |
SI-BONE, Inc.
NASDAQ:SIBN
Intrinsic Alpha fair value
Locked
Current Price
$23.54
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.